pubmed-article:10190948 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:10190948 | lifeskim:mentions | umls-concept:C0013216 | lld:lifeskim |
pubmed-article:10190948 | lifeskim:mentions | umls-concept:C0026764 | lld:lifeskim |
pubmed-article:10190948 | lifeskim:mentions | umls-concept:C2349179 | lld:lifeskim |
pubmed-article:10190948 | lifeskim:mentions | umls-concept:C0205390 | lld:lifeskim |
pubmed-article:10190948 | pubmed:issue | 4 | lld:pubmed |
pubmed-article:10190948 | pubmed:dateCreated | 1999-6-24 | lld:pubmed |
pubmed-article:10190948 | pubmed:abstractText | In multiple myeloma (MM) patients treated with conventional chemotherapy, the attainment and duration of a plateau phase seems to affect survival more than the degree of response to initial treatment. The aims of this study are: 1) to analyze within a cohort of previously untreated MM patients the incidence and the duration of the plateau phase; 2) to correlate it with the presenting features; 3) to assess its impact on survival. | lld:pubmed |
pubmed-article:10190948 | pubmed:language | eng | lld:pubmed |
pubmed-article:10190948 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:10190948 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:10190948 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:10190948 | pubmed:month | Apr | lld:pubmed |
pubmed-article:10190948 | pubmed:issn | 0390-6078 | lld:pubmed |
pubmed-article:10190948 | pubmed:author | pubmed-author:BernasconiCC | lld:pubmed |
pubmed-article:10190948 | pubmed:author | pubmed-author:LazzarinoMM | lld:pubmed |
pubmed-article:10190948 | pubmed:author | pubmed-author:CorsoAA | lld:pubmed |
pubmed-article:10190948 | pubmed:author | pubmed-author:KlersyCC | lld:pubmed |
pubmed-article:10190948 | pubmed:author | pubmed-author:ArcainiLL | lld:pubmed |
pubmed-article:10190948 | pubmed:author | pubmed-author:NozzaAA | lld:pubmed |
pubmed-article:10190948 | pubmed:author | pubmed-author:ZappasodiPP | lld:pubmed |
pubmed-article:10190948 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:10190948 | pubmed:volume | 84 | lld:pubmed |
pubmed-article:10190948 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:10190948 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:10190948 | pubmed:pagination | 336-41 | lld:pubmed |
pubmed-article:10190948 | pubmed:dateRevised | 2006-4-24 | lld:pubmed |
pubmed-article:10190948 | pubmed:meshHeading | pubmed-meshheading:10190948... | lld:pubmed |
pubmed-article:10190948 | pubmed:meshHeading | pubmed-meshheading:10190948... | lld:pubmed |
pubmed-article:10190948 | pubmed:meshHeading | pubmed-meshheading:10190948... | lld:pubmed |
pubmed-article:10190948 | pubmed:meshHeading | pubmed-meshheading:10190948... | lld:pubmed |
pubmed-article:10190948 | pubmed:meshHeading | pubmed-meshheading:10190948... | lld:pubmed |
pubmed-article:10190948 | pubmed:meshHeading | pubmed-meshheading:10190948... | lld:pubmed |
pubmed-article:10190948 | pubmed:meshHeading | pubmed-meshheading:10190948... | lld:pubmed |
pubmed-article:10190948 | pubmed:meshHeading | pubmed-meshheading:10190948... | lld:pubmed |
pubmed-article:10190948 | pubmed:meshHeading | pubmed-meshheading:10190948... | lld:pubmed |
pubmed-article:10190948 | pubmed:meshHeading | pubmed-meshheading:10190948... | lld:pubmed |
pubmed-article:10190948 | pubmed:meshHeading | pubmed-meshheading:10190948... | lld:pubmed |
pubmed-article:10190948 | pubmed:meshHeading | pubmed-meshheading:10190948... | lld:pubmed |
pubmed-article:10190948 | pubmed:year | 1999 | lld:pubmed |
pubmed-article:10190948 | pubmed:articleTitle | Plateau phase in multiple myeloma: an end-point of conventional-dose chemotherapy. | lld:pubmed |
pubmed-article:10190948 | pubmed:affiliation | Institute of Hematology, University of Pavia, IRCCS Policlinico San Matteo, 27100 Pavia, Italy. a.corso@smatteo.pv.it | lld:pubmed |
pubmed-article:10190948 | pubmed:publicationType | Journal Article | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10190948 | lld:pubmed |